Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1NSCLC 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Clinical Trials, Phase I as Topic × Clear all
NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Aragon Pharmaceuticals, Inc.

Phase 1/2 Completed
127 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT04402008 2024-06-25

Study of Poziotinib in Japanese Patients With NSCLC

Spectrum Pharmaceuticals, Inc

Phase 1/2 Terminated
42 enrolled 16 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡